FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
58.684,57 -743,80 (-1,25%)
Ovid Therapeutics Inc. (1OT.F)
| Chiusura precedente | 2,9000 |
| Aperto | 2,7600 |
| Denaro | 2,8800 x 0 |
| Lettera | 2,9200 x 0 |
| Min-Max giorno | 2,7600 - 2,7600 |
| Intervallo di 52 settimane | 2,4600 - 3,6800 |
| Volume | |
| Media Volume | 15 |
| Capitalizzazione | 204,332M |
| Beta (5 anni mensile) | 0,69 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,6900 |
| Prossima data utili | 03 mag 2024 - 07 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 4,75 |
GlobeNewswireOvid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a presentation at the Jefferies Inaugural Biotech CNS/Neuro Summit on Thursday, October 12, 2023, at 3:30 p.m. ET in New York. A live webcast of the Jefferies presentation can be accessed through the Events & Presentation
- GlobeNewswire
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that it will host a Research & Development (R&D) Day investor event on Monday, October 2, 2023. The event will take place at the Company’s headquarters in New York’s Hudson Yards from 12:00 pm - 2:30 pm and will be webcast simultaneously. Ovid management w
- GlobeNewswire
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET in New York, New York. A live webcast of the Cantor Fitzgerald presentation can be accessed
